News headlines about T2 Biosystems (NASDAQ:TTOO) have trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. T2 Biosystems earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 46.8525346763692 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern’s analysis:
- T2 Biosystems Reports Granting of Inducement Awards (finance.yahoo.com)
- T2 Biosystems (TTOO) Rating Reiterated by Canaccord Genuity (americanbankingnews.com)
- T2 Biosystems (TTOO) Rating Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- T2 Biosystems (TTOO) Upgraded to Buy at Zacks Investment Research (americanbankingnews.com)
- $1.40 Million in Sales Expected for T2 Biosystems Inc (TTOO) This Quarter (americanbankingnews.com)
T2 Biosystems stock traded down $0.09 during trading hours on Thursday, hitting $6.80. 237,134 shares of the stock traded hands, compared to its average volume of 329,353. The company has a debt-to-equity ratio of 1.29, a quick ratio of 0.83 and a current ratio of 0.86. The stock has a market cap of $238.45, a price-to-earnings ratio of -3.24 and a beta of 1.20. T2 Biosystems has a one year low of $2.50 and a one year high of $7.26.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.